Javed Anees: An Evidence-Based Clinical Guide to ESA Therapy
Javed Anees, Medical Consultant at Government of Kerala, shared a post on LinkedIn:
“Erythropoiesis-Stimulating Agents (ESAs) have transformed the management of anemia in chronic kidney disease and selected oncology patients by reducing transfusion requirements and improving quality of life. However, appropriate patient selection, correction of reversible causes, and careful monitoring remain essential to maximize benefit while minimizing cardiovascular and thromboembolic risks.
This evidence-based infographic summarizes:
- Indications for ESA therapy
- When to initiate treatment in CKD and dialysis
- Pre-treatment evaluation and iron optimization
- Target hemoglobin and dose adjustment
- Contraindications and adverse effects
- Causes of ESA hyporesponsiveness
- HIF-prolyl hydroxylase inhibitors and other alternatives
- Practical clinical pearls aligned with current guideline recommendations
A key reminder:
ESA therapy should be individualized – not driven by hemoglobin alone. Correct iron deficiency and other reversible causes first, use the lowest effective ESA dose to reduce transfusion needs, and avoid targeting normal hemoglobin levels. In most CKD patients, a hemoglobin around 10–11.5 g/dL is the preferred therapeutic range.
I hope this infographic serves as a concise, practical reference for residents, physicians, nephrologists, internists, and trainees involved in anemia management.”

Other posts featuring Javed Anees on Hemostasis Today.
-
Nov 21, 2026, 20:00Jeyda Star: The FAST Signs of Stroke and the Reality of Life Afterward
-
Nov 21, 2026, 19:59Daniel Lindholm: Women Showed the Largest Improvement in Stroke Risk Over Time in Heart Failure
-
Nov 21, 2026, 19:56Neil Arrowsmith: Raising Awareness of Pulmonary Embolism in Young People
-
Nov 21, 2026, 19:52Muhammad Zeeshan Jamal: Thrilled to Present Our Research on Intermediate-Risk Acute PE in Abu Dhabi
-
Nov 21, 2026, 19:50Mounisha Devireddy: Proud to Share Our Research on High-Risk PE in Pregnancy
-
Nov 21, 2026, 19:47Melissa Hollo: How Severe Anemia Increases the Odds of Acute HF During Pregnancy and Postpartum
-
Nov 21, 2026, 19:44Ashenafi Tazebew Amare: Building Sustainable Systems to Close the Anti-D Immunoglobulin Access Gap in LMICs
-
Nov 21, 2026, 19:43Sheharyar Raza: Interpreting Clotting Times Through Reptilase Time and Thrombin Time Assays
-
Nov 21, 2026, 19:42Minoo Ahmadinejad: Serving on the ISTH 2027 Scientific Theme Committee for Women’s Health